S402
Clinical - Gynaecological
ESTRO 2026
free survival (DFS) were both not reached. The 2-year OS rate was 93%, and the 1- and 2-year DFS rates were 81% and 65%, respectively. Significant associations were found between higher percentage decreases ( Δ ) in metabolic/volumetric parameters (SUVmax, SUVmean, MTV and TLG) and improved DFS for both interim and post- treatment comparisons. Optimal cutoff values for PET1–PET2 were SUVmax, SUVmean, MTV and TLG at 66%, 63%, 72%, and 91%, respectively. The corresponding PET1–PET3 cutoffs were 75%, 75%, 72%, and 92%, respectively. Patients exceeding these thresholds had significantly longer DFS. In PET1–PET2, Δ SUVmax ≥ 66% corresponded to 2-year DFS of 78% vs. 46% for <66%; while Δ SUVmean >63% corresponded to 2y-DFS of 87% vs. 35% for ≤ %63. In PET1–PET3, Δ SUVmax >75% showed 2-year DFS of 75% vs. 25%, and Δ SUVmean >75% showed 86% vs. 25%. Interim PET/CT complete response (CR) was strongly correlated with absence of recurrence, and PET/CT-based volumetric changes showed superior prognostic performance compared to MRI-based measurements. Conclusion: Interim and early post-treatment FDG-PET/CT provide valuable and quantifiable prognostic information in LACC, enabling early identification of high-risk patients. Metabolic response assessment during treatment should be incorporated to guide adaptive therapeutic strategies and improve patient outcomes. References: 1. Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024. 74(3): p. 229-263.2. Ferrari, M., et al., Interim (18)FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic review. Crit Rev Oncol Hematol, 2017. 113: p. 28-42.3. Krhili, S., et al., Use of Metabolic Parameters as Prognostic Factors During Concomitant Chemoradiotherapy for
Locally Advanced Cervical Cancer. Am J Clin Oncol, 2017. 40(3): p. 250-255. Keywords: cervical cancer, FDG-PET/CT, metabolic response,
Proffered Paper 653
The Endoscopy Results of rhSOD in Concurrent Chemoradiotherapy for Cervical Cancer to Prevent Rectal Injury: A Prospective Multi-Center Trial Jiawei Zhu 1 , Manni Huang 2 , Xiaofan Li 3 , Hong Zhu 4 , Yan Tan 5 , Xia He 6 , Zhihua Sun 6 , Huijun Cheng 7 , Fenghu Li 8 , Ping Jiang 9 , Hanmei Lou 10 , Guihao Ke 11 , Xinping Cao 12 , Lihong Zhu 13 , Peng Xie 14 , Junfang Yan 1 , Fuquan Zhang 1 1 Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. 2 Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3 Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China. 4 Oncology, Xiangya Hospital, Central South University, Changsha, China. 5 Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Chengdu, China. 6 Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute ofCancer Research, The Affiliated Cancer Ho spital of Nanjing Medical University, Nanjing, China. 7 Gynecological Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. 8 Oncology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China. 9 Radiation Oncology, Peking University 3rd Hospital, Beijing, China. 10 Gynecological Oncology, Zhejiang Cancer hospital, Hangzhou, China. 11 Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 12 Radiation Oncology, Sun Yat-sen University
Made with FlippingBook - Share PDF online